Patients with chronic spontaneous urticaria experienced substantial reductions in hives and itch with briquilimab through 16 ...

Jane Street Group LLC bought a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR – Free Report) during the third quarter, ...

Jasper Therapeutics (NASDAQ:JSPR – Get Free Report) had its price objective reduced by HC Wainwright from $60.00 to $40.00 in ...

Alyea Therapeutics to Present at Biotech Showcase 2025 During 43rd Annual J.P. Morgan Healthcare Conference Week ...

City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy ...

Jasper Therapeutics Inc (JSPR) stock saw a decline, ending the day at $6.99 which represents a decrease of $-10.72 or -60.53% from the prior close of $17.71. The stock opened at $8.74 and touched a ...

The board of supervisors awarded both contracts to Manatt’s, Inc., who will be tasked with the resurfacing and milling of ...

Analyst Justin Zelin of BTIG reiterated a Buy rating on Jasper Therapeutics (JSPR – Research Report), reducing the price target to $64.00.Stay ...

Jasper Therapeutics continued building out the data for a drug designed to treat irritable skin conditions, though the latest ...

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) reported preliminary data from the ongoing BEACON Phase 1b/2a study of subcutaneous ...

Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile ...